Antibodies and methods for generating genetically altered...

Details Antibodies and methods for generating genetically altered... Antibodies and methods for generating genetically altered...

2008-10-15

2010-10-05

Rawlings, Stephen L (Department: 1643)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Using tissue cell culture to make a protein or polypeptide

C435S069100, C435S070100, C435S071100, C435S326000, C435S328000, C530S387300, C530S388100

Reexamination Certificate

active

07807416

ABSTRACT:
Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into cells and transgenic animals, new cell lines and animal varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation. These methods are useful for generating genetic diversity within immunoglobulin genes directed against an antigen of interest to produce altered antibodies with enhanced biochemical activity. Moreover, these methods are useful for generating antibody-producing cells with increased level of antibody production. The invention also provides methods for increasing the effector function of monoclonal antibodies and monoclonal antibodies with increased effector function.

REFERENCES:
patent: 5530101 (1996-06-01), Queen et al.
patent: 6808894 (2004-10-01), Nicolaides et al.
patent: 7235643 (2007-06-01), Nicolaides et al.
patent: 7604994 (2009-10-01), Grasso et al.
patent: 7671179 (2010-03-01), Nicolaides et al.
patent: 2003/0143682 (2003-07-01), Nicolaides et al.
patent: 2004/0237125 (2004-11-01), Nicolaides et al.
patent: 2005/0054048 (2005-03-01), Grasso et al.
patent: 2006/0204506 (2006-09-01), Ebel et al.
patent: 2006/0239910 (2006-10-01), Nicolaides et al.
patent: 2006/0239911 (2006-10-01), Nicolaides et al.
patent: 2007/0244302 (2007-10-01), Nicolaides et al.
patent: 2009/0274697 (2009-11-01), Grasso et al.
patent: 2010/0021454 (2010-01-01), Nicolaides et al.
patent: 2240609 (1999-10-01), None
patent: WO 01/32712 (2001-05-01), None
patent: WO 02/37967 (2002-05-01), None
patent: WO 02/054856 (2002-07-01), None
patent: WO 2004/024871 (2004-03-01), None
patent: WO 2005/011735 (2005-02-01), None
patent: WO2005011735 (2005-02-01), None
Li et al. (Proc. Natl. Acad. Sci. USA. Mar. 7, 2006; 103 (10): 3557-3562).
Nicolaides et al. (Ann. n. Y. Acad. Sci. 2005; 1059: 86-96).
Iglesias-Ussel et al. (J. Immunol. Methods. 2006; 316: 59-66).
Glaudet et al. (Eur. J. Immunol. 2004; 34: 1637-1645).
Peron et al. (J. Exp. Med. Oct. 27, 2008; 205 (11): 2465-2472).
Schrader et al. (J. Exp. Med. Aug. 2, 1999; 190 (3): 323-3300).
Alsmadi, O., et al., “Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities,” J. of Virol., 1998, 72(1), 286-293.
Baker, S.M., et al., “Male defective in the DNA mismatch repair gene PMS2 exhibit abnormal chromosome synapsis in meiosis,” Cell, 1995, 309-319, vol. 82; No . 2.
Bignami, M., “Unmasking a killer: DNA O(6)-methylguanine and the cytotoxicity of methylating agents,” Mutat. Res., 2000, 462, 71-82.
Bronner, C.E., et al., “Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer,” Nature, 1994, 368, 258-261.
Clynes, R., et al., “Fc receptors are required in passive and active immunity to melanoma,” Proc. Natl. Acad. Sci. USA, 1998, 95, 652-656.
Clynes, R.,A., et al., “Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets,” Nat. Med., 2000, 6(4), 443-446.
Coney, L.R., et al., “Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein,” Cancer Res., 1991, 51, 6125-6132.
Crameri, A.,et al., “Combinatorial multiple cassette mutagenesis creates all the permutations of mutant and wild-type sequences,” BioTechniques, 1995, 18(2), 194-196.
deWind, N., et al., “Inactivation of the mouse Msh2, gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer,” Cell, 1995, 82, 321-330.
Drummond, J.T., et al., “Isolation of an hMSH2-p160 heterodimer that restores mismatch repair to tumor cells,” Science, 1995, 268, 1909-1912.
Drummond, J.T., et al., “Cisplatin and adriamycin resistance are associated with MutLα and mismatch repair deficiency in an ovarian tumor cell line,” J. Biol. Chem., 1996, 271(33), 19645-19648.
Emery, S.C., et al., “Strategies for humanizing antibodies,” in Antibody Engineering, C.A.K. Borrebaeck (Ed.), Oxford University Press, 1995, 159-183.
Eshleman, J.R., et al., “Mismatch repair defects in human carcinogensis,” Hum. Mol. Genet., 1996, 5,1489-1494.
Fiedler, U., et al., “High-level production and long-term storage of engineered antibodies in transgenic tobacco seeds,” Bio/Technology, 1995, 13, 1090-1093.
Frigerio, L., et al., “Assembly, secretion, and vacuolar delivery of a hybrid immunoglobulin in plants,” Plant Physiol., 2000, 123, 1483-1494.
Galio, L., et al., “ATP hydrolysis-dependent formation of a dynamic ternary nucleoprotein complex with MutS and MutL,” Nucl. Acids Res., 1999, 27(11), 2325-2331.
Garin-Chesa, P., “Trophoblast and ovarian cancer antigen LK26,” Am. J. Pathol., 1993, 142(2), 557-567.
Glaser, V., “Can reopro repolish tarnished monoclonal therapeutics?” Nat. Biotechnol., 1996, 14, 1216-1217.
Haught, C., et al., “A method to insert a DNA fragment into a double-stranded plasmid,” BioTechniques, 1994, 16(1), 46-48.
Israel, E.J., et al., “Increased clearance of IgG in mice that lack β2-microglobulin: possible protective role of FcRn,” Immunology, 1996, 89, 573-578.
Khazaeli, M.B., et al., “Human immune response to monoclonal antibodies,” J. of Immunother., 1994, 15, 42-52.
Kunkel, T.A., et al., “[6] Efficient site-directed mutagenesis using uracil-containing DNA,” Methods in Enzymol., 1991, 204, 125-139.
Liu, T., et al., “Microsatellite instability as a predictor of a mutation in a DNA mismatch repair gene in familial colorectal cancer,” Genes, Chromosomes Cancer, 2000, 27, 17-25.
McCall, A.M., et al., “Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity,” J. of Immunol., 2001, 166, 6112-6117.
Modrich, P., “Mismatch repair, genetic stability, and cancer,” Science, 1994, 266, 1959-1960.
Neuberger, M., et al., “Monoclonal antibodies: Mice perform a human repertoire,” Nature, 1997, 386, 25-26.
Newkirk, M.M., et al., “Differential clearance of glycoforms of IgG in normal and antoimmune-prone mice,” Clin. Exp. lmmun., 1996, 106, 259-264.
Nicolaides, N.C., et al., “Analysis of the 5' region of PMS2 reveals heterogenous transcripts and a novel overlapping gene,” Genomics, 1995, 29, 329-334.
Nicolaides, N.C., et al., “Genomic organization of the human PMS2 gene family,” Genomics, 1995, 30, 195-206.
Nicolaides, N.C., el al., “The Jun family members, c-JUN and JUND, transactivate the human c-myb promoter via an Ap1 like element,” J. Biol. Chem., 1992, 267(27), 19665-19672..
Nicolaides, N.C., “A naturally occurring hPMS2 mutation can confer a dominant negative mutator phenotype,” Mol. Cell. Biol., 1998, 18(3), 1635-1641.
Palombo, F., et al., “Mismatch repair and cancer,” , Nature, 1994, 367, p. 417.
Papadopoulous, N., et al., “Mutation of a mutL homolog is associated with hereditary colon cancer,” 1993, 263, 1625-1629.
Parsons, R., et al., “Hypermutability and mismatch repair deficiency in RER+tumor cells,” Cell, 1993, 75, 1227-1236.
Perucho, M., “Cancer of the microsatellite mutator phenotype,” Biol. Chem., 1996, 377, 675-684.
Prolla, T.A., et al., “MLH1, PMS1, and MSH2 interaction during initiation of DNA mismatch repair in yeast,” Science, 1994, 265, 1091-1093.
Raju, T.S., “Glycosylation variations with expression systems and their impact on biological activity of therapeutic immunoglobulins,” BioProcess International, 2003, 44-53.
Reff, M.E., “High-level production of recombinant immunoglobulins in mammalian cells,ȁ

Affiliated with

Also associated with

Rating

Antibodies and methods for generating genetically altered... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies and methods for generating genetically altered..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies and methods for generating genetically altered... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4207438